Elmiron Pigmentary Maculopathy lawsuit settlement criteria
Since our initial coverage of the Elmiron litigation wave, the legal landscape surrounding pentosan polysulfate sodium (PPS) maculopathy has matured significantly. As of early 2026, the multidistrict litigation (MDL) in the District of New Jersey has established clear, tiered settlement criteria that directly impact thousands of former Elmiron users. We are now seeing the first wave of binding settlement agreements executed, with compensation amounts tied to objective retinal imaging findings and duration of drug exposure. This article provides the current, actionable criteria patients and attorneys need to evaluate claims today.
Judge Michael A. Shipp’s 2025 Daubert Ruling and the Revised Exposure Thresholds
The pivotal moment in this litigation came in late 2025 when Judge Shipp issued a Daubert ruling that validated the core scientific link between Elmiron and pigmentary maculopathy, while also establishing minimum cumulative exposure thresholds. The court accepted expert testimony showing that clinically significant retinal toxicity rarely occurs below 1,500 grams of cumulative PPS exposure—roughly equivalent to seven years of continuous daily use at the standard 300 mg dose. This ruling effectively eliminated claims from short-term users and forced plaintiffs to produce objective evidence of cumulative dosing. The settlement criteria now universally require pharmacy records or prescription histories that document at least 1,500 grams of lifetime PPS intake.
The Daubert gatekeeping function has been instrumental in narrowing this litigation to credible claims. As we noted in our 2024 analysis, the scientific consensus has shifted from "possible association" to "established causation" for long-term users. For the full legal context, see the MDL docket at f1000prime.com and the archived reference at web.archive.org.
Three-Tier Compensation Matrix Based on OCT and Visual Field Severity
The settlement framework adopted in 2026 uses a tiered system that correlates payout ranges with objective retinal damage classifications. Optical coherence tomography (OCT) findings and Humphrey visual field (HVF) results form the backbone of this stratification. Below is the current compensation matrix as negotiated between the Plaintiffs’ Steering Committee and Janssen Pharmaceuticals:
| Tier | OCT/HVF Findings | Cumulative Exposure | Estimated Compensation Range |
|---|---|---|---|
| 1 | Subclinical pigmentary changes; no visual field loss | 1,500–2,500 grams | $25,000 – $75,000 |
| 2 | Definite maculopathy with paracentral scotomas; >5 dB loss | 2,500–4,000 grams | $100,000 – $250,000 |
| 3 | Advanced maculopathy with central vision loss; >10 dB loss or legal blindness | 4,000+ grams | $350,000 – $750,000+ |
We emphasize that these ranges represent base compensation before factoring in special damages for lost wages, medical expenses, and pain and suffering. Tier 3 cases with bilateral legal blindness have seen settlements exceeding $1.2 million in individual negotiations outside the MDL framework.
Required Documentation and the Statute of Limitations Clock in 2026
To successfully file a claim under the current settlement criteria, plaintiffs must assemble a specific package of evidence. The courts have become strict about incomplete submissions, and we have seen several claims dismissed for lack of pharmacy records alone. Here is the documentation checklist we recommend all prospective claimants gather immediately:
- Pharmacy dispensing records covering the entire period of Elmiron use, including drug name, dosage, quantity dispensed, and fill dates. If original records are unavailable, affidavits from prescribing physicians may be accepted in limited circumstances.
- Baseline and follow-up OCT imaging from a board-certified retina specialist, with explicit notation of pigmentary changes in the macula, vitelliform deposits, or photoreceptor loss.
- Humphrey visual field (24-2 or 10-2) tests demonstrating reproducible paracentral or central scotomas consistent with drug-induced toxicity.
- Exclusion of alternative diagnoses such as age-related macular degeneration, pattern dystrophy, or Stargardt disease, confirmed by genetic testing if indicated.
- Proof of diagnosis date relative to the statute of limitations in the plaintiff’s state of residence. Most states have a 2–3 year window from discovery, and we are seeing a surge of claims from patients diagnosed between 2020 and 2023 who are approaching the filing deadline.
The statute of limitations remains the single greatest barrier to recovery in 2026. We strongly advise any patient who used Elmiron for more than five years and has noticed visual changes—even subtle ones—to undergo a comprehensive retinal evaluation immediately. The settlement fund established by Janssen has finite capacity, and early filers within each tier have historically received preferential consideration.
As the litigation enters its final phase, we continue to monitor developments in the MDL and will update these criteria as new rulings emerge. For patients who meet the exposure and diagnostic thresholds, the window for filing a compensable claim remains open—but it is closing rapidly.